stockrowLantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −17.1%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
Follow LNTH
Alert me
Lantheus Holdings, Inc. (LNTH) EBITDA
Lantheus Holdings, Inc.'s EBITDA for fiscal 2025 was $385.4M, down 26.7% from $525.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $386.4M. Over the past ten years it has ranged from −$17.9M (fiscal 2021) to $525.9M (fiscal 2024); the current reading is higher than 82% of that period. Lantheus Holdings, Inc. ranks 13th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $385.4M | (26.72%) |
| FY2024 | $525.9M | 22.59% |
| FY2023 | $429.0M | 402.48% |
| FY2022 | $85.4M | — |
| FY2021 | −$17.9M | — |
| FY2020 | $20.6M | (68.78%) |
| FY2019 | $66.0M | (17.16%) |
| FY2018 | $79.7M | 10.01% |
| FY2017 | $72.4M | (5.24%) |
| FY2016 | $76.5M | 17.90% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $56.2M | (54.63%) |
| Jun 2026 | $123.9M | 17.87% |
| Mar 2026 | $105.1M | 3.95% |
| Dec 2025 | $101.1M | 55.26% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| SUPN Indivior Pharmaceuticals Inc. compare | $571.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| LNTH Lantheus Holdings, Inc. | $386.4M |
| ALKS Alkermes plc compare | $217.3M |
| LQDA Liquidia Corporation compare | $170.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$165.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LNTH
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement